Chemistry:Utreloxastat
From HandWiki
Utreloxastat (PTC857) is an investigational new drug developed by PTC Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS).[1]
Pharmacology
Utreloxastat is a 15-lipoxygenase (15-LO) inhibitor that has been used to study α-synucleinopathies, tauopathies, traumatic brain injury, and ischemic-reperfusion related injuries. Utreloxastat is a redox‐active inhibitor of ferroptosis.[2]
Clinical trials
Utreloxastat has reached Phase 2 clinical trials for the treatment of amyotrophic lateral sclerosis (ALS).[3][4][5] However this trial failed to show significant efficacy in slowing disease progression.[6]
See also
References
- ↑ "Utreloxastat - PTC Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800057140.
- ↑ "Utreloxastat". MedChemExpress. https://www.medchemexpress.com/utreloxastat.html.
- ↑ "First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis". Clinical Pharmacology in Drug Development 12 (2): 141–151. February 2023. doi:10.1002/cpdd.1203. PMID 36516010.
- ↑ "CARDINALS: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Utreloxastat (PTC857) in Patients with Amyotrophic Lateral Sclerosis (P5-11.010)". Neurology 102 (17_supplement_1). 2024-04-14. doi:10.1212/WNL.0000000000205241. https://www.neurology.org/doi/10.1212/WNL.0000000000205241.
- ↑ "Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis". Expert Opinion on Emerging Drugs 29 (2): 93–102. June 2024. doi:10.1080/14728214.2024.2333420. PMID 38516735.
- ↑ "PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients". PTC Therapeutics, Inc.. 26 November 2024. https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-topline-results-cardinals-trial.
 |  |
